The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 03, 2020

Filed:

Jan. 10, 2019
Applicant:

Bioway., Inc, Gangwon-Do, KR;

Inventors:

Jongwoo Kim, Gyeonggi-do, KR;

Chiwoo Lee, Gyeonggi-do, KR;

Suji Hong, Gangwon-Do, KR;

Assignee:

BIOWAY., INC, , KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01); C07D 239/91 (2006.01); C07D 473/34 (2006.01); A61P 1/16 (2006.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01); A61P 37/00 (2006.01);
U.S. Cl.
CPC ...
C07D 473/34 (2013.01); A61P 1/16 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61P 37/00 (2018.01); C07D 239/91 (2013.01);
Abstract

The present invention relates to novel quinazolinone derivatives inhibiting PI3K; a method for preparing the derivatives; and a pharmaceutical composition for treating hematologic neoplasms or liver diseases, containing the quinazolinone derivatives, wherein the novel quinazolinone derivatives according to the present invention have a beneficial effect in the treatment of hematologic neoplasms or liver diseases. Particularly, the quinazolinone derivatives inhibit PI3Kδ with high selectivity compared to that of a conventional anticancer drug of PI3Kδ inhibitors, thereby significantly reducing immunotoxicity, or simultaneously inhibit PI3Kδ and PI3Kγ, thereby enabling the treatment of autoimmune diseases, and anticancer therapy for blood cancer and the like. These targeted drugs have reduced side effects. The present invention provides a compound represented by Formula 1 or a pharmaceutically acceptable salt thereof, wherein X is —H, halogen, —CH, or —NH; and Y is Clinear alkyl or Ccycloalkyl.


Find Patent Forward Citations

Loading…